Access to device-aided therapies in advanced Parkinson’s disease: navigating clinician biases, patient preference, and prognostic uncertainty
Journal of Neural Transmission · 2023-11 · 130 (11) · 1411-1432
DOI: 10.1007/s00702-023-02668-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Neural Transmission, online erschienen am 12.07.2023. Verfasst von Manon Auffret und 4 weiteren Autor:innen. Beteiligte Einrichtung: France Développement Electronique (FDE), Monswiller, France. auffret.manon@gmail.com. Hauptthemen laut MEDLINE: Parkinson Disease, Deep Brain Stimulation. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 217 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Device-aided therapies (DAT), which include deep brain stimulation and pump-based continuous dopaminergic stimulation with either levodopa or apomorphine, are among the major advances in the clinical management of Parkinson’s disease (PD). Although DAT are being increasingly offered earlier in the disease course, their classical indication remains advanced PD. Theoretically, every patient should be offered transition to DAT when faced with refractory motor and nonmotor fluctuations and functional decline. Worldwide clinical reality is far from these ideal, and, therefore, question the “real-world” equal opportunity of access to DAT for PD patients with advanced PD—even within a single health care system. Differences in access to care, referral pattern (timing and frequency), as well as physician biases (unconscious/implicit or conscious/explicit bias), and patients’ preferences or health-seeking behaviour are to be considered. Compared to DBS, little information is available concerning infusion therapies, as well as neurologists’ and patients’ attitudes towards them. This viewpoint aims to be thought-provoking and to assist clinicians in moving through the process of DAT selection, by including in their decision algorithm their own biases, patient perspective, ethical concerns as well as the current unknowns surrounding PD prognosis and DAT-related long-term side effects for a given patient.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- France Développement Electronique (FDE), Monswiller, France. auffret.manon@gmail.com.
- Institut des Neurosciences Cliniques de Rennes (INCR), Rennes, France. auffret.manon@gmail.com.
- Behavior and Basal Ganglia Research Unit, CIC-IT, CIC1414, Pontchaillou University Hospital and University of Rennes, Rennes, France. auffret.manon@gmail.com.
- Centre for Neurology, Department for Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research, Hoppe-Seyler-Str. 3, 72076, Tübingen, Germany.
- University San Raffaele Roma and Institute of Research and Medical Care IRCCS San Raffaele Roma, Rome, Italy.
- Institut des Neurosciences Cliniques de Rennes (INCR), Rennes, France.
ORCID-Profile: Manon Auffret
Zitieren
APA
Auffret, M., Weiss, D., Stocchi, F., Vérin, M., & Jost, W. H. (2023). Access to device-aided therapies in advanced Parkinson’s disease: navigating clinician biases, patient preference, and prognostic uncertainty. Journal of Neural Transmission, 130(11), 1411-1432. https://doi.org/10.1007/s00702-023-02668-9
Vancouver
Auffret M, Weiss D, Stocchi F, Vérin M, Jost WH. Access to device-aided therapies in advanced Parkinson’s disease: navigating clinician biases, patient preference, and prognostic uncertainty. Journal of Neural Transmission. 2023;130(11):1411-1432. doi:10.1007/s00702-023-02668-9
BibTeX
@article{Auffret2023,
author = {Auffret, Manon and Weiss, Daniel and Stocchi, Fabrizio and Vérin, Marc and Jost, Wolfgang H},
title = {Access to device-aided therapies in advanced Parkinson’s disease: navigating clinician biases, patient preference, and prognostic uncertainty},
journal = {Journal of Neural Transmission},
year = {2023},
volume = {130},
number = {11},
pages = {1411--1432},
doi = {10.1007/s00702-023-02668-9}
}
EUVIMED